PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16919261-2	2006	The objectives of the present study were to determine the effects of azelnidipine, a new calcium channel blocker, on the expression of VCAM-1 induced by 7-ketocholesterol, components of ox-LDL, and tumor necrosis factor-alpha (TNF-alpha).	7-ketocholesterol	153-170	vascular cell adhesion molecule 1	Homo sapiens	135-141	
16919261-6	2006	The surface expression and mRNA levels of VCAM-1 were determined by enzyme immunoassay and RT-PCR performed on endothelial cell monolayers stimulated with 7-ketocholesterol or TNF-alpha.	7-ketocholesterol	155-172	vascular cell adhesion molecule 1	Homo sapiens	42-48	
16919261-13	2006	These results suggest that azelnidipine works as an anti-atherogenic agent by inhibiting the reactive oxygen species-dependent expression of VCAM-1 induced by 7-ketocholesterol and TNF-alpha.	7-ketocholesterol	159-176	vascular cell adhesion molecule 1	Homo sapiens	141-147